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Abstract
The interface between psychiatry and stress-related gastrointestinal disorders (GI), such as irritable bowel syndrome
(IBS), is well established, with anxiety and depression the most frequently occurring comorbid conditions. Moreover,
stress-sensitive Wistar Kyoto (WKY) rats, which display anxiety- and depressive-like behaviors, exhibit GI
disturbances akin to those observed in stress-related GI disorders. Additionally, there is mounting preclinical and
clinical evidence implicating mast cells as significant contributors to the development of abdominal visceral pain in
IBS. In this study we examined the effects of the rat connective tissue mast cell (CTMC) stabiliser, disodium
cromoglycate (DSCG) on visceral hypersensitivity and colonic ion transport, and examined both colonic and
peritoneal mast cells from stress-sensitive WKY rats. DSCG significantly decreased abdominal pain behaviors
induced by colorectal distension in WKY animals independent of a reduction in colonic rat mast cell mediator release.
We further demonstrated that mast cell-stimulated colonic ion transport was sensitive to inhibition by the mast cell
stabiliser DSCG, an effect only observed in stress-sensitive rats. Moreover, CTMC-like mast cells were significantly
increased in the colonic submucosa of WKY animals, and we observed a significant increase in the proportion of
intermediate, or immature, peritoneal mast cells relative to control animals. Collectively our data further support a role
for mast cells in the pathogenesis of stress-related GI disorders.
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Introduction
Abdominal visceral pain and altered bowel habits are
cardinal symptoms of the stress-related gastrointestinal (GI)
disorder, irritable bowel syndrome (IBS) [1,2]. Moreover, the
interface between psychiatry and IBS is well established, with
anxiety and depressive disorders the most frequently occurring
comorbid conditions [3]. It is therefore not surprising that rodent
models of anxiety and depression, such as the Wistar Kyoto
(WKY) rat [4], display GI features akin to those associated with
IBS, for example increased abdominal visceral pain [5-7],
reduced colonic accommodation [8] and altered colonic fluid
and electrolyte transport [9,10], all key pathophysiological
features which support the use of the WKY rat as a valid pre-
clinical paradigm for examining stress-related GI disorders, and
in particular IBS [11].
The evidence to date implicating mast cells in the
pathogenesis and pathophysiology of IBS [12-15], and the
contribution of their mediators to the development of visceral
hypersensitivity [12,13,16,17] is robust, and supports the
targeting of mast cells in the management of stress-related GI
disorders. However, not all preclinical models of visceral
hypersensitivity display significantly increased colonic mucosal
mast cells (MMC) [18-20], and we have previously observed a
distinct increase in colonic submucosal, connective tissue-like,
mast cells following early life stress [18]. Moreover, the effects
of the mast cell stabiliser, doxantrazole on abdominal pain
have yielded conflicting results in rat models of visceral
hypersensitivity [18,19,21,22]. However, the selectivity of mast
cell stabilisers for specific mast cell populations has been
exploited to confirm mast cell heterogeneity with respect to
mast cell mediator release [23], and to discriminate the
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contribution of MMC from connective tissue mast cells (CTMC)
on GI function in the rat [24,25]. Therefore, in this study we
have examined the effects of the CTMC stabiliser [26],
disodium cromoglycate (DSCG) on abdominal visceral pain in a
stress-sensitive rat strain. Additionally, given the association
between stress-related GI disorders and altered bowel habit,
we sought to examine the effects of DSCG on colonic secretory
function in anxiety-prone WKY rats.
Materials and Methods
Ethics statement
All animal experimentation was approved by the University
College Cork Animal Experimentation Ethics Committee and
conducted in accordance with the European Community
Council directive (86/69/EEC).
Animals
Male weight-matched anxiety-prone WKY and normo-
anxious Sprague Dawley rats (SD; 250-300g) were purchased
from Harlan U.K. (Bicester, Oxon, United Kingdom). Animals
were maintained under standard controlled conditions with a 12
hour light/dark cycle (lights on 7.00am). Rats were allowed to
acclimatise for one week prior to experimentation, were briefly
handled daily, though were not habituated to the colorectal
distension (CRD) environment. Food and water were available
ad libitum, with the exception of those animals used for CRD,
which were fasted overnight before experimentation.
Colorectal distension
CRD was conducted as previously described in detail by our
group [27]. Rats were briefly anaesthetised with isoflurane and
a latex balloon (6 cm in length) was inserted into the
descending colon 1 cm from the anus. Animals were allowed to
recover for 10 minutes before undergoing CRD. The balloon
was connected to a barostat controlled by a computer using
Protocol plus TM distension software (G&J electronic, Toronto,
Ontario, Canada), and was inflated from 0-80 mm Hg over 8
minutes. During this time, the pressure at which the first pain
behaviour was observed (threshold), and total number of
visceral pain behaviours were visually recorded by an observer
blinded to the experimental groups. Given the short half-life of
DSCG [28] animals were treated 24, 6 and 1 hour prior to CRD
with vehicle (saline), 25 mg kg-1 or 50 mg kg-1 DSCG
intraperitoneally (i.p.). Previous studies have used a similar
pre-treatment regimen to stabilise rat submucosal mast cells
[29], and doses of DSCG in the range of 10 mg kg-1 to 50 mg
kg-1 i.p. have previously been demonstrated to decrease nerve
damage-induced hyperalgesia [29], inhibit mast cell activation
[30] and protect against gastroduodenal ulcers [31] in rats.
Assessment of colonic mast cell inhibition
To determine whether in vivo administration of DSCG
stabilised colonic mast cells, following CRD animals were
euthanized by carbon dioxide (CO2) inhalation and distal colon
samples (1cm proximal to the anus) were collected for analysis
of RMCPII and histamine. Briefly, 3 cm segments of distal
colon were rapidly immersed in 2 ml Hanks balance salt
solution (HBSS) in 5 ml tubes oxygenated with carbogen gas
(95% O2/5% CO2), maintained at 37°C and stimulated with
compound 48/80 (10 μg ml-1; Sigma-Aldrich) for 30 minutes in a
shaking water bath. Aliquots of stimulated colon supernatants
were frozen at -80°C prior to assessment of rat mast cell
protease II (RMCPII; Moredun Scientific Limited) or histamine
(Labor Diagnostika Nord GmbH & Co, KG, Nordhorn,
Germany) release by enzyme-linked immunosorbent assay kits
according to the manufacturer’s instructions.
Colonic ion transport
In a separate group of WKY and SD animals we assessed
the sensitivity of short circuit current (Isc) to compound 48/80
(10 µg ml-1) and DSCG (10-3M) in vitro. Animals were
euthanized by CO2 inhalation, after which descending colon
samples (collected up to 6 cm proximal to the rectum) were
obtained, carefully rinsed of any faecal matter and the circular
and longitudinal muscle layers, along with the myenteric
plexus, removed by blunt dissection. Colon segments were
then placed in NaviCyte vertical Ussing chambers (Harvard
Apparatus, Kent, United Kingdom), and each side of the tissue
was bathed in 5 ml of circulating oxygenated (95% O2/5% CO2)
Krebs buffer (1.2 mM NaH2PO4 , 117mM NaCl, 4.8mM KCl,
1.2mM MgCl2, 25mM NaHCO3, 11mM CaCl2, 10mM glucose)
maintained at 37°C. Tissues were then voltage clamped at 0
mV (EVC-4000 or DVC-1000; World Precision Instruments,
Sarasota, Florida, United States of America) and short-circuit
current (Isc) digitally recorded (LabTrax 4/16; World Precision
Instruments) and analysed using DataTrax 2 software (World
Precision Instruments). Tissues were allowed to stabilise for 30
minutes after which either vehicle or DSCG were added (30
minutes), followed by either vehicle or compound 48/80 for 1
hour. Bethanechol (100 μM; Sigma-Aldrich) and forskolin (10
μM; Sigma-Aldrich) were added at the end of each experiment.
All drug additions were to the basolateral half of the Ussing
chamber. Tissues were not paired, and WKY and SD
preparations were usually carried out on different days. Results
were converted to μA.cm-2.
Immunohistochemical and histochemical identification
of submucosal mast cells from Wistar Kyoto rats
Descending colon samples were collected from
experimentally naïve animals and were fixed in 4%
paraformaldehyde, cryo-preserved in 30% sucrose and
subsequently cryostat sectioned at 12 μm. For histological
identification of mast cells, Alcian blue (Sigma-Aldrich, Poole,
United Kingdom) and safranin (Sigma-Aldrich) staining was
conducted as described by others [17], and previously used by
our group to identify submucosal mast cells in rat colon [18].
Briefly, slides were rinsed for 1 minute in 10 mM PBS, and then
incubated for 1 minute in 0.125N hydrochloric acid (HCL).
Slides were then incubated for 1 hour with 1% Alcian blue in
0.7N HCL, for 1 minute in 0.125N HCL followed by 2 minutes
incubation with 0.5% safranin in 0.125N HCL. Slides were
subsequently dehydrated and mounted with DPX mounting
media. For immunohistochemical staining of RMCP II, sections
were incubated overnight in a humidified chamber at 4°C with
Cromolyn: Effects on Colonic Pain and Function
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sheep anti-rat RMCPII (1:500; Moredun Scientific Limited,
Midlothian, Scotland), after which sections were incubated with
a cyanine-conjugated secondary antibody (1:100; Jackson
ImmunoResearch Laboratory Inc, Suffolk, United Kingdom) for
two hours at room temperature. Slides were finally washed and
mounted with bicarbonate buffered glycerol and stored at 4°C.
Histochemical identification of peritoneal mast cells
from Wistar Kyoto rats
To isolate peritoneal mast cells, animals were first
euthanized by CO2 inhalation after which 20 ml of sterile
physiological saline was injected into the peritoneal cavity and
the area massaged for 5 minutes. Peritoneal exudates were
collected and filtered through a 70 µm cell strainer, centrifuged
at 1200 rpm for 5 minutes and re-suspended in 1 ml of sterile
physiological saline. Mast cells were then purified by Percoll
density gradient as previously described [32]. The purified mast
cells were then cytocentrifuged at 350 x g for 5 minutes onto
glass slides and were left to dry overnight before fixation in
Carnoy’s fixative. Mast cells were then stained with Alcian blue
and safranin as outlined above.
Mast cell quantification
Colonic submucosal mast cells were counted and classified
as Alcian blue, safranin or RMCPII positive. For submucosal
cell counts, cells present in 3 sections, randomly selected from
3 slides per animal (n=9-15 animals) were quantified, and were
subsequently expressed as total number of mast cells per
section given the low numbers of cells observed. For
quantification of RMCPII-containing MMC, sections and slides
were similarly selected, however given the significantly greater
numbers of MMC per section, the number of RMCPII immuno-
positive cells per mm2 were quantified in a similar manner to
that previously reported by our laboratory [18]. Peritoneal mast
cells were classified based on their Alcian blue or safranin
staining characteristics, and were expressed as a percentage
of total mast cells per slide.
Statistical analysis
Data are expressed as mean +/- standard error of the mean
throughout. p<0.05 was considered significant. Colonic mast
cell counts were analysed using an unpaired one-tailed
Student’s t-test and peritoneal mast cells were analysed using
a two-way analysis of variance (ANOVA) followed by LSD post
hoc test. Threshold and total number of pain behaviours
between WKY and SD tissues were analysed using a Student’s
t-test. Comparisons between vehicle, 25 mg kg-1 or 50 mg kg-1
DSCG on threshold, total number of pain behaviours and
release of RMCPII and histamine were analysed using one-
way ANOVA followed by Bonferroni’s multiple comparison
post-test. Changes in Isc in response to compound 48/80 and
DSCG were analysed using two-way ANOVA followed by LSD
post hoc test. All statistical analysis was performed using
SPSS 14.0 for Windows.
Results
Disodium cromoglycate inhibits visceral
hypersensitivity in stress-sensitive Wistar Kyoto rats
WKY rats displayed a viscerally hypersensitive phenotype
relative to SD animals (Figure 1 A and B), and this was
sensitive, in a dose-dependent manner, to pre-treatment with
DSCG (F(2, 23)=12.5, p<0.001 (threshold); (F(2, 21)=5.99,
p<0.05 (total pain behaviours)), where 50mg kg-1 DSCG
significantly increased threshold (p<0.01; Figure 1C) and
significantly decreased total pain behaviours (p<0.05; Figure
1D).
Colonic release mast cell mediators is insensitive to
inhibition by disodium cromoglycate
Vehicle-treated WKY animals displayed significantly greater
compound 48/80-stimulated RMCPII release relative to vehicle-
treated SD tissues (t(13)=3.33, p<0.01; Figure 2A). However,
this was not the case for histamine (Figure 2B), and neither
RMCPII nor histamine release were significantly different
between WKY and SD tissues following pre-treatment with
either dose of DSCG (Figure 2C and D).
Disodium cromoglycate inhibits both compound 48/80-
stimulated and forskolin (cAMP)-stimulated electrolyte
transport in Wistar Kyoto rat colon
The compound 48/80-induced Isc response was significantly
diminished in WKY colon relative to SD tissues (F
(1,57),=77.69, p<0.001), and this response was sensitive to
inhibition by DSCG in WKY tissues only (p<0.01; Figure 3A).
Similarly, the forskolin-induced increase in Isc was only
sensitive to inhibition by DSCG in WKY colon (F(1,56)=6.29,
p<0.05; Figure 3B).
Stress-sensitive Wistar Kyoto rats display increased
colonic submucosal and intermediate peritoneal mast
cells
An equal proportion of rat colonic submucosal mast cells
may be expected to stain positively for Alcian blue and safranin
[33]. However in stress-sensitive WKY animals, submucosal
mast cells stained almost exclusively with Alcian blue;
significantly more of which were observed in the colonic
submucosa of distal sections obtained from WKY animals
relative to those from normo-anxious SD rats (t (18)=1.6,
p<0.05; Figure 4A & B). Moreover, significantly greater
numbers of submucosal mast cells expressed RMCPII relative
to SD tissues (t (17)=2.7, p<0.01; Figure 4 C & D). We found
no significant difference in the number of RMCPII-containing
MMC between the distal colons of WKY and SD animals (WKY,
53.7 ± 4.0 mast cells/mm2 versus SD, 48.6 ± 2.6 mast cells/
mm2, n=10)
To further characterise mast cells in stress-sensitive WKY
animals, we isolated peritoneal mast cells from WKY and SD
rats. Using a previously described classification method
[34,35], our analysis revealed a significant difference between
mast cell staining characteristics (F(1,24)=17.84, p<0.001) and
a significant interaction between rat strain and mast cell
Cromolyn: Effects on Colonic Pain and Function
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staining (F(1,24)=8.18, p<0.01). In stress-sensitive WKY rats,
approximately 50% of the isolated mast cells displayed classic
CTMC staining (safranin positive), significantly less than that
observed in SD rats (p< 0.05), with the majority of the
remaining mast cells displaying an intermediate (Alcian blue/
safranin) staining pattern (Figure 4 E & F).
Discussion
Disodium cromoglycate reverses visceral
hypersensitivity independent of colonic mast cell
stabilisation
A heightened response to CRD is a characteristic feature of
stress-sensitive WKY animals [5-7,36], and, as mast cells have
been implicated in the development of stress-induced visceral
hypersensitivity in rats [18,21,37,38], we examined the dose-
dependent effect of the mast cells stabiliser, DSCG on visceral
hypersensitivity in WKY animals. We specifically selected
DSCG based on its proposed selectivity for rat CTMC [26], and
on our previous observation of increased colonic CTMC-like
mast cells in an early life stress stress-induced model of
visceral hypersensitivity [18]. Moreover, DSCG has previously
been demonstrated to significantly inhibit nerve injury-induced
hyperalgesia in rats [29]. However, to the best of our
knowledge, DSCG has not been examined with respect to its
effects on abdominal visceral hypersensitivity. In this context,
DSCG ameliorated the threshold to first pain behaviour, and
total number of pain behaviors, induced by CRD in viscerally
hypersensitive WKY rats, at the highest dose tested. However,
the inhibition of the visceromotor response to CRD occurs
independent of a significant inhibition of colonic RMCPII or
histamine release from tissues exposed to DSCG in vivo.
Despite not reaching statistical significance, we did observe an
approximate 30% reduction in colonic RMCPII release from
animals treated with 50 mg Kg-1DSCG. While we hypothesise
that the increased compound 48/80-stimulated RMCPII release
in WKY rats may originate from increased submucosal
RMCPII-containing mast cells, stabilisation of CTMC-like cells
with DSCG may also result in a loss of CTMC-mediated
inhibition of MMC mediator release, previously described in rat
airways [39]. Moreover, the lack of inhibition observed with
respect to stimulation of histamine release by compound 48/80
is in keeping with previous reports on compound 48/80-
stimulated release from intestinal mast cells [40]. Collectively,
these data point toward a partial inhibition of mast cells by
DSCG, but also suggest that the inhibition of visceral
hypersensitivity by DSCG may occur independent of colonic
mast cell stabilisation. Furthermore, previous studies have
demonstrated a significant inhibitory effect of DSCG (10 mg
Kg-1) on serum histamine levels following IgE-dependant mast
cell activation in vivo [30]. Therefore, we cannot exclude the
possibility that DSCG, in our study, may have stabilised
Figure 1.  Disodium cromoglycate inhibits visceral hypersensitivity in stress-prone Wistar Kyoto rats.  Colorectal distension-
induced pain behaviors in Wistar Kyoto (WKY) animals were significantly greater than those observed in Sprague Dawley (SD)
animals (A, threshold; B, total pain behaviours). Pre-treatment with 50 mg kg-1 disodium cromoglycate (DSCG) significantly
increased the pressure required to induce the first pain behaviour (C, threshold) and decreased the total number of pain behaviours
(D) in WKY animals. n= 7-8. * p<0.05, ** p <0.01, versus SD. # p <0.05, ## p <0.01, versus vehicle.
doi: 10.1371/journal.pone.0084718.g001
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peritoneal mast cells relative to intestinal mast cells, as we did
not assess systemic markers of mast cell stabilisation.
However, DSCG has also been shown to directly influence
nociceptive signalling through an inhibition of capsaicin-
induced activity of sensory nerve endings [41], and can inhibit
substance P binding [42]. The inhibition of visceral
hypersensitivity in WKY rats may also reflect a non-specific
analgesic effect of the mast cell stabiliser, particularly as we did
not assess the effects of DSCG in SD rats. However, Zuo et
al., (2003) observed no significant effect of DSCG on hind paw
responses to mechanical or thermal hyperalgesia when they
examined the contralateral side of animals who had undergone
partial ligation of the left sciatic nerve [29]. Moreover, DSCG
can inhibit enteric nerve excitation [43] and intestinal
contractility [44], both of which may influence the response to
CRD. Intriguingly however, DSCG, at the same dose as that
used in our study (50 mg Kg-1; i.p.), significantly improved
anxiety-like behaviours in rats exposed to acute restraint stress
[45]. Though we did not assess anxiety-like behaviours in our
animals following treatment with DSCG, the anxiolytic
properties of the drug may have influenced the response to
CRD in WKY rats.
Therefore, the mechanism by which DSCG reverses the
visceral pain response in stress-sensitive animals remains
unclear, but is likely to involve several mechanisms, not only
limited to mast cells, but also including direct effects on visceral
nociceptors, intestinal physiology and centrally-mediated
behaviour.
Influence of compound 48/80 and disodium
cromoglycate on colonic short-circuit current
Despite the absence of a significant inhibitory effect of DSCG
on colonic mast cell mediator release from WKY tissues,
compound 48/80-stimulated RMCPII release was significantly
increased relative to SD colon. As previous studies have
demonstrated an influence of RMCPII on intestinal ion
transport [46], and given we observed CTMC-like mast cells in
the submucosa of WKY rat colon, we examined the effects of
the CTMC activator, compound 48/80 and CTMC inhibitor,
DSCG on colonic ion transport in submucosal-mucosal colonic
preparations. Previous studies, albeit in chicken ileal
preparations, previously characterised the compound 48/80-
induced change Isc to be histaminergic and sensitive to
inhibition with the mast cell stabiliser, ketotifen, and the
histamine receptor 1 antagonist, mepyramine [47]. Despite
observing an increased number of submucosal mast cells in
WKY tissues, the compound 48/80 response was significantly
decreased in WKY colon relative to that observed in tissues
from normo-anxious SD animals. However, more recent data
have identified a mast cell independent, direct effect, of
compound 48/80 on submucosal neurones [43]. Therefore, our
data may indicate a change in enteric nervous system
neuroplasticity or in the neurochemistry of submucosal
neurones in WKY rat colon. Moreover, DSCG appears to exert
a non-selective inhibitory effect on enteric nerve excitation [43].
Therefore, further investigation is warranted into teasing apart
Figure 2.  Stimulated release of colonic mast cell mediators was insensitive to inhibition by disodium
cromoglycate.  Compound 48/80 (10 µg ml-1)-stimulated RMCPII release was significantly greater from Wistar Kyoto (WKY) colons
relative to Sprague Dawley (SD; A) tissues and was insensitive to inhibition by DSCG (C). Similarly, histamine release was neither
elevated from WKY colon relative to SD tissues (B), nor sensitive to inhibition by DSCG (D). n= 7-8. ** p <0.01, versus SD.
doi: 10.1371/journal.pone.0084718.g002
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the mast cell- and neuronal-components of the compound
40/80-induced change in Isc in rat colon. Nontheless, only
WKY tissues displayed altered sensitivity to both compounds.
The mechanism for this differential sensitivity to DSCG
between SD and WKY rats remains uninvestigated, but may be
due to strain-related differences in the response to compound
48/80 [48]. Moreover, the inhibitory effects of DSCG can be
enhanced by additional factors, for example alterations in
cAMP or sympathetic activity [49], which may be relevant in our
study, given WKY tissues displayed an increased Isc response
to the cAMP activator, forskolin, though this did not reach
significance. Moreover, others have demonstrated an inhibition
of corticotrophin releasing factor-induced Isc by the mast cell
stabiliser, doxantrazole [50], receptors for which our group
previously found to be altered in the colon of WKY animals
[51]. Therefore, these data suggest that locally, in the colon,
and in a strain dependant manner, DSCG can inhibit either
mast cell- or neurally-stimulated Isc. And although forskolin-
stimulated Isc was reduced in WKY tissues in the presence of
DSCG, the resultant Isc was no different to that observed in
control, SD tissues.
Figure 3.  Wistar Kyoto rat colon displays altered
sensitivity to compound 48/80 and disodium cromoglycate
in vitro.  The change in short-circuit current (Isc) induced by
compound 48/80 was significantly decreased in Wistar Kyoto
(WKY) colon, and sensitive to inhibition by disodium
cromoglycate (DSCG; A). Though WKY and Sprague Dawley
tissues responded in a similar manner to forskolin stimulation,
only the WKY response was sensitive to inhibition by DSCG.
n=7-8, ** p <0.01, *** p<0.001, versus SD. # p <0.05, ## p
<0.01, versus vehicle.
doi: 10.1371/journal.pone.0084718.g003
Characterisation of colonic and peritoneal mast cells
from stress-sensitive rats
In stress-sensitive WKY animals we observed an increase in
colonic submucosal mast cells, similar to our previous findings
in a rat model of early life stress [18]. In particular, these mast
cells were Alcian blue positive, with few if any safranin positive
mast cells observed, and they displayed characteristics of
CTMC, such as resistance to paraformaldehyde fixation [52].
Our findings are in contrast to previous studies, in which equal
proportions of Alcian blue and safranin positive mast cells were
observed in the rat colonic submucosa [33]. Therefore, we
speculate that the Alcian blue positive mast cells observed in
the WKY colonic submucosa most likely reflect a population
rich in chondroitin sulphate and low in heparin [53].
In contrast to the colon, a significant proportion of peritoneal
mast cells obtained from WKY rats displayed Alcian blue/
safranin staining characteristics with a concomitant, and
significant, decrease in safranin CTMC relative to control SD
rats; in which the majority of peritoneal mast cells were safranin
positive, a classic feature of CTMC [54,55]. These Alcian blue/
safranin intermediate mast cells may not only reflect an
immature mast cell population [35], but also a population in a
trans-differentiated state, the process whereby mature mast
cells change the content of their cytoplasmic granules [56,57]
or reversibly acquire features of immature mast cells in
response to the local microenvironment [58,59]. Intermediate
mast cells may also represent increased mast cell turnover
[60]. However, the microenvironmental factors influencing the
characteristics of colonic and peritoneal mast cells in WKY rats
remains unexplored, and likely include a variety of factors
including cytokines, neurotransmitters and lipid-derived
mediators among others, which are also most likely to vary
depending on their tissue localisation. Nonetheless, we have
observed alterations in both the number (colon) and
classification (peritoneal) of mast cells in stress-sensitive rats,
and we speculate that such alterations may be associated with
the anxiety-like phenotype of WKY rats given the evidence that
inhibition of mast cells, with DSCG, influences anxiety-like
behaviours in vivo [45,61].
Concluding remarks
We have demonstrated that DSCG displays efficacy in
reducing abdominal visceral pain, though the precise
mechanism is likely multi-faceted, and not solely due to colonic
mast cell stabilisation. Moreover, we identified that compound
48/80-induced responses in the colon of WKY animals were
sensitive to inhibition with DSCG, and this may account for the
symptom improvement (bowel movement and stool
consistency) observed in diarrhoea-predominant IBS patients
treated with the drug [62].We have further shown that mast cell
number and classification, in the colon and peritoneum, are
increased and altered respectively in a stress-sensitive animal
model of visceral hypersensitivity. This coupled with our
previous work on the impact of early life stress on mast cell
phenotype, and the development of visceral hypersensitivity
[18], highlights a role not just for mast cells in the pathogenesis
of stress-related GI disorders, but also their heterogeneity.
However, alterations in mast cells are likely to occur
Cromolyn: Effects on Colonic Pain and Function
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downstream of local microenvironmental influences,
investigations of such milieu is now warranted.
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Figure 4.  Changes in submucosal mast cell number and peritoneal mast cell classification in Wistar Kyoto rats.  Colons
from Wistar Kyoto (WKY) animals displayed a significantly greater number of Alcian blue (A and B, black arrow head) and RMCPII
(C and D, white arrow head) positive submucosal connective tissue mast cells relative to Sprague Dawley (SD; insert) animals (*
p<0.05, ** p<0.01 versus SD, n=10-15). Purified peritoneal mast cells isolated from SD animals were predominantly safranin
positive (F, black arrow head), and therefore considered CTMC, while equal proportions of those isolated from WKY animals were
either safranin positive or Alcian blue/safranin positive (F; white arrow heads), representing CTMC and intermediate mast cells
respectively. n=4. * p<0.05, versus s+. # p<0.05, ## p<0.01, versus SD.
doi: 10.1371/journal.pone.0084718.g004
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